TC BioPharm Achieves Major Milestone in Cancer Treatment Releasing Complete Response Data

TC BioPharm Reports Success in Treatment of Minimal Residual Disease

On June 11, 2025, TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a pioneering biotechnology firm focused on gamma delta T cell therapies for cancer treatment, announced an extraordinary development concerning its clinical trials. The company's lead drug candidate, TCB008, has shown promising results in a patient with Minimal Residual Disease (MRD), achieving complete molecular remission. This groundbreaking announcement marks a significant milestone in TC BioPharm’s quest to innovate cell therapies aimed at targeting and eradicating malignant cells effectively.

The first patient in Cohort B of the clinical trial, who had previously been diagnosed with detectable MRD, received two doses of the TCB008 therapy. Remarkably, after receiving a total of 500 million gamma delta T cells, the patient entered a state of complete molecular remission. The second dose, administered two weeks after the initial treatment, played a crucial role in this positive outcome. The patient is currently under the care of Dr. Hugues de Lavallade at Guy’s and St. Thomas’ NHS Foundation Trust, where they continue to be monitored closely, two months post-treatment.

This data dissemination is more than just a number; it represents a substantial achievement in achieving effective treatments for blood cancer, an affliction impacting over one million patients each year globally. Many of these individuals face great challenges as they attempt to maintain remission; even after achieving it, they often have underlying molecular burdens that can lead to relapse. The complexity of these cases is further exacerbated by previous treatment regimens, which can narrow the options available to relapsed patients.

Dr. Hugues de Lavallade, a consultant hematologist, expressed optimism about the implications of this patient’s response, noting that they had experienced molecular relapse despite ongoing low-intensity chemotherapy. Upon detecting rising NPM1 transcript levels—an indicator of MRD—the chemotherapy was halted. Remarkably, after administration of TCB008 following lymphodepletion, the patient demonstrated a substantial reversal of their condition, entering complete molecular remission with no detectable NPM1 transcripts remaining.

“Seeing such a positive patient response is invigorating for our team,” commented Bryan Kobel, CEO of TC BioPharm. He believes that TCB008 may establish itself as a crucial component of post-remission therapy for patients battling blood cancers, extending their survival rates and improving overall long-term outcomes. Additionally, TCB008 could serve as an impactful monotherapy for newly diagnosed patients seeking to avoid the grueling pathway of a bone marrow transplant.

Kobel emphasized the importance of effectively treating MRD, stating that it may stop the progression of the disease before it has a chance to resurface. The therapeutic potential of TCB008 and its targeted immune activity continues to show promise, and with this encouraging response, TC BioPharm’s commitment to this patient population and its innovative approach remain steadfast.

In addition to TCB008, TC BioPharm is leading the exploration of gamma delta T cell therapies and is the first entity to conduct significant phase II/pivotal clinical studies in oncology. The company’s focus on this unmodified gamma delta T cell product line comprises two ongoing investigator-initiated clinical trials. One of these pivotal trials focuses on employing their proprietary CryoTC technology to treat acute myeloid leukemia, characterized by the provision of frozen T cell products that can be delivered to clinics globally.

This landmark achievement undoubtedly places TC BioPharm at the forefront of innovation in cancer therapeutics. As they continue to navigate the complexities of MRD and focus their research on enhancing outcomes for patients with blood cancers, the world eagerly anticipates further developments and breakthroughs from this trailblazing biopharmaceutical company.